Boston Scientific Corporation (BSX) Key Metrics
BSX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $64.33B
- Enterprise value
- $76.75B
- P/E (TTM)
- 18.0 10-yr median 58.6
- Forward P/E
- 13.2
- PEG ratio
- 0.63
- Price / sales
- 3.1 10-yr median 5.2
- Price / book
- 2.6 10-yr median 4.5
- EV / EBITDA
- 13.6 10-yr median 28.0
- Dividend yield
- —
- Beta
- 0.57
BSX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBSX valuation Price multiples at each fiscal year-end price.
BSX returns How much profit the business earns on the capital it uses.
BSX per-share figures Results divided by the shares outstanding at year-end.
BSX financial health Debt, liquidity and how easily interest is covered.
BSX efficiency & capital use Working capital cycle and where the cash goes.
BSX valuation history
BSX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BSX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BSX cash returned to shareholders
BSX price vs earnings per share
BSX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $142.50B | $132.72B | $84.60B | $66.61B | $60.91B | $50.93B | $63.79B | $49.53B | $34.53B | $29.79B |
| Enterprise value | $152.87B | $143.45B | $93.23B | $74.97B | $68.43B | $58.74B | $73.85B | $56.44B | $39.95B | $35.08B |
| P/E ratio | 49.4 | 71.6 | 53.1 | 95.4 | 58.6 | — | 13.6 | 29.6 | 332.0 | 85.8 |
| Price / sales | 7.1 | 7.9 | 5.9 | 5.3 | 5.1 | 5.1 | 5.9 | 5.0 | 3.8 | 3.6 |
| Price / book | 5.9 | 6.1 | 4.4 | 3.8 | 3.7 | 3.3 | 4.6 | 5.7 | 4.9 | 4.4 |
| Price / free cash flow | 39.0 | 50.2 | 49.7 | 72.9 | 46.3 | 45.0 | 46.4 | — | 31.2 | 50.0 |
| Price / operating cash flow | 31.4 | 38.6 | 33.8 | 43.7 | 32.6 | 33.8 | 34.7 | 159.8 | 24.2 | 30.6 |
| EV / sales | 7.6 | 8.6 | 6.5 | 5.9 | 5.8 | 5.9 | 6.9 | 5.7 | 4.4 | 4.2 |
| EV / EBITDA | 30.0 | 36.4 | 27.0 | 27.4 | 27.2 | 38.8 | 33.4 | 21.8 | 19.9 | 28.6 |
| EV / free cash flow | 41.8 | 54.2 | 54.7 | 82.0 | 52.0 | 51.9 | 53.7 | — | 36.1 | 58.9 |
| Earnings yield | 2.0% | 1.4% | 1.9% | 1.0% | 1.7% | −0.2% | 7.4% | 3.4% | 0.3% | 1.2% |
| Free cash flow yield | 2.6% | 2.0% | 2.0% | 1.4% | 2.2% | 2.2% | 2.2% | −0.0% | 3.2% | 2.0% |
| Dividend yield | — | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | 0.0% | 0.1% | 0.1% | 0.0% |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 1.1% | 0.0% | 0.1% | 0.1% | 0.0% |
| Share price at fiscal year-end | $95.35 | $89.32 | $57.81 | $46.27 | $42.48 | $35.95 | $45.22 | $35.34 | $24.79 | $21.63 |
| Per share | ||||||||||
| Revenue per share | $13.43 | $11.27 | $9.73 | $8.81 | $8.29 | $7.00 | $7.61 | $7.01 | $6.50 | $6.09 |
| Earnings per share | $1.93 | $1.25 | $1.09 | $0.48 | $0.73 | −$0.06 | $3.33 | $1.19 | $0.07 | $0.25 |
| Operating cash flow per share | $3.03 | $2.31 | $1.71 | $1.06 | $1.30 | $1.06 | $1.30 | $0.22 | $1.02 | $0.71 |
| Free cash flow per share | $2.45 | $1.78 | $1.16 | $0.63 | $0.92 | $0.80 | $0.97 | −$0.00 | $0.79 | $0.43 |
| Cash per share | $1.37 | $0.28 | $0.59 | $0.64 | $1.34 | $1.22 | $0.15 | $0.10 | $0.13 | $0.14 |
| Book value per share | $16.21 | $14.65 | $13.18 | $12.21 | $11.59 | $10.82 | $9.84 | $6.23 | $5.03 | $4.89 |
| Tangible book value per share | −$0.71 | −$1.35 | −$0.76 | −$0.87 | −$1.04 | −$0.38 | −$2.97 | −$3.97 | −$4.18 | −$4.23 |
| Dividends per share | — | $0.00 | $0.02 | $0.04 | $0.04 | $0.02 | $0.02 | $0.02 | $0.02 | $0.00 |
| Capex per share | $0.59 | $0.53 | $0.55 | $0.43 | $0.39 | $0.27 | $0.33 | $0.23 | $0.23 | $0.27 |
| Debt per share | $8.31 | $7.50 | $6.49 | $6.45 | $6.59 | $6.73 | $7.29 | $5.03 | $4.03 | $3.98 |
| Shares outstanding | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B | 1.40B | 1.39B | 1.38B |
| Change in shares outstanding | +0.6% | +1.5% | +1.7% | +0.4% | +1.2% | +0.4% | +0.7% | +0.6% | +1.1% | +2.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 12.5% | 9.0% | 8.6% | 4.1% | 6.5% | −0.6% | 41.6% | 21.2% | 1.5% | 5.3% |
| Return on invested capital (ROIC) | 10.1% | 7.1% | 6.5% | 4.5% | 7.9% | 2.0% | 8.7% | 12.4% | 6.2% | 10.4% |
| Return on assets (ROA) | 6.9% | 5.0% | 4.7% | 2.2% | 3.3% | −0.3% | 18.2% | 8.3% | 0.6% | 1.9% |
| Return on tangible assets | 15.7% | 11.9% | 10.8% | 5.1% | 7.4% | −0.5% | 37.6% | 24.9% | 1.7% | 6.3% |
| Free cash flow margin | 18.2% | 15.8% | 12.0% | 7.2% | 11.1% | 11.4% | 12.8% | −0.1% | 12.2% | 7.1% |
| Income quality (OCF / net income) | 1.57 | 1.85 | 1.57 | 2.19 | 1.80 | — | 0.39 | 0.19 | 13.71 | 2.80 |
| Financial health | ||||||||||
| Total debt | $12.42B | $11.15B | $9.49B | $9.28B | $9.45B | $9.54B | $10.28B | $7.06B | $5.62B | $5.48B |
| Cash & short-term investments | $2.04B | $414.0M | $865.0M | $928.0M | $1.93B | $1.73B | $217.0M | $146.0M | $188.0M | $196.0M |
| Net debt | $10.37B | $10.73B | $8.63B | $8.35B | $7.53B | $7.80B | $10.06B | $6.91B | $5.43B | $5.29B |
| Debt / equity | 0.51 | 0.51 | 0.49 | 0.53 | 0.57 | 0.62 | 0.74 | 0.81 | 0.80 | 0.81 |
| Debt / assets | 0.28 | 0.28 | 0.27 | 0.29 | 0.29 | 0.31 | 0.34 | 0.34 | 0.29 | 0.30 |
| Net debt / EBITDA | 2.03 | 2.73 | 2.50 | 3.05 | 2.99 | 5.16 | 4.55 | 2.67 | 2.70 | 4.31 |
| Current ratio | 1.62 | 1.08 | 1.32 | 1.51 | 1.48 | 1.82 | 0.97 | 0.76 | 0.68 | 0.90 |
| Quick ratio | 1.08 | 0.64 | 0.82 | 1.02 | 1.10 | 1.45 | 0.64 | 0.54 | 0.49 | 0.64 |
| Interest coverage | 11.4 | 6.8 | 8.0 | 3.9 | 5.5 | 1.3 | 3.3 | 6.5 | 6.6 | 5.3 |
| Working capital | $3.35B | $521.0M | $1.58B | $1.96B | $2.04B | $3.01B | −$167.0M | −$1.26B | −$1.83B | −$348.0M |
| Invested capital | $34.61B | $32.50B | $27.91B | $25.93B | $24.15B | $23.13B | $23.94B | $15.63B | $12.44B | $12.02B |
| Tangible asset value | −$829.0M | −$1.77B | −$860.0M | −$1.25B | −$1.49B | −$540.0M | −$4.18B | −$5.56B | −$5.82B | −$5.83B |
| Net current asset value | −$10.41B | −$10.47B | −$9.09B | −$9.14B | −$9.29B | −$8.76B | −$11.99B | −$8.27B | −$8.21B | −$8.12B |
| Graham number | $26.54 | $20.28 | $17.96 | $11.54 | $13.76 | — | $27.16 | $12.92 | $2.91 | $5.26 |
| Graham net-net per share | −$9.03 | −$9.19 | −$8.08 | −$8.03 | −$8.05 | −$8.40 | −$10.14 | −$7.38 | −$7.28 | −$6.96 |
| Capital allocation | ||||||||||
| Dividends paid | — | $0 | $28.0M | $55.0M | $55.0M | $28.0M | $28.0M | $28.0M | $28.0M | $0 |
| Share buybacks (net) | $0 | $0 | $0 | $0 | $0 | $535.0M | $0 | $0 | $0 | $0 |
| Dividend payout ratio | — | 0.0% | 1.8% | 7.9% | 5.3% | — | 0.6% | 1.7% | 26.9% | 0.0% |
| Dividends + buybacks / free cash flow | 0.0% | 0.0% | 1.6% | 6.0% | 4.2% | 49.7% | 2.0% | — | 2.5% | 0.0% |
| Capex / revenue | 4.4% | 4.7% | 5.6% | 4.8% | 4.7% | 3.8% | 4.3% | 3.2% | 3.5% | 4.5% |
| Capex / operating cash flow | 19.3% | 23.0% | 32.0% | 40.1% | 29.6% | 24.9% | 25.1% | 101.9% | 22.4% | 38.7% |
| Capex / depreciation | 0.64 | 0.62 | 0.67 | 0.54 | 0.51 | 0.33 | 0.46 | 0.35 | 0.38 | 0.46 |
| Stock-based compensation / revenue | 1.5% | 1.6% | 1.6% | 1.7% | 1.6% | 1.7% | 1.5% | 1.4% | 1.4% | 1.4% |
| R&D / revenue | 10.2% | 9.6% | 9.9% | 10.4% | 10.1% | 11.5% | 10.9% | 11.3% | 11.0% | 11.0% |
| SG&A / revenue | 34.3% | 35.7% | 34.9% | 35.6% | 36.7% | 38.2% | 36.7% | 36.3% | 36.4% | 37.0% |
| Efficiency | ||||||||||
| Days sales outstanding | 49.9 | 52.2 | 53.8 | 53.9 | 50.8 | 61.8 | 58.4 | 58.6 | 60.9 | 59.8 |
| Days of inventory on hand | 168.8 | 149.1 | 146.8 | 127.7 | 122.1 | 123.3 | 129.9 | 122.4 | 116.8 | 118.2 |
| Days payables outstanding | 61.7 | 53.6 | 60.9 | 60.8 | 53.9 | 44.4 | 42.2 | 47.9 | 56.1 | 39.3 |
| Cash conversion cycle (days) | 156.9 | 147.7 | 139.7 | 120.8 | 119.0 | 140.7 | 146.2 | 133.1 | 121.6 | 138.6 |
| Receivables turnover | 7.32 | 7.00 | 6.78 | 6.77 | 7.19 | 5.90 | 6.25 | 6.22 | 5.99 | 6.11 |
| Payables turnover | 5.91 | 6.81 | 6.00 | 6.00 | 6.77 | 8.22 | 8.66 | 7.61 | 6.50 | 9.28 |
| Inventory turnover | 2.16 | 2.45 | 2.49 | 2.86 | 2.99 | 2.96 | 2.81 | 2.98 | 3.13 | 3.09 |
| Asset turnover | 0.48 | 0.45 | 0.42 | 0.39 | 0.38 | 0.32 | 0.42 | 0.49 | 0.49 | 0.46 |
| Average receivables | $2.74B | $2.39B | $2.10B | $1.87B | $1.65B | $1.68B | $1.72B | $1.58B | $1.51B | $1.37B |
| Average payables | $1.05B | $951.0M | $902.0M | $828.0M | $653.5M | $527.5M | $445.5M | $439.5M | $488.5M | $328.0M |
| Average inventory | $2.88B | $2.65B | $2.18B | $1.74B | $1.48B | $1.47B | $1.37B | $1.12B | $1.02B | $985.5M |
| Intangibles / total assets | 57.9% | 60.3% | 58.0% | 58.0% | 56.2% | 51.6% | 59.1% | 68.0% | 67.4% | 69.4% |
Computed from BSX's annual financial statements (latest annual report filed February 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BSX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Boston Scientific traded at 49.4 times earnings, against a 10-year median of 58.6. Based on the latest twelve months, the trailing P/E is 18.0 and the forward P/E is 13.2. Boston Scientific earned a return on equity of 12.5% and a return on invested capital of 10.1% in fiscal 2025. It ended the year with $12.4 billion of debt and $2.0 billion in cash and short-term investments, net debt of $10.4 billion. The share count rose 8.5% from 1.38B to 1.49B over 9 years.
See the BSX income statement, the BSX chart for price history, or the BSX stock overview for the latest quote and news.
BSX key metrics FAQ
What is Boston Scientific's P/E ratio?
Boston Scientific's trailing P/E ratio is 18.0 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 13.2. At the end of fiscal 2025 it was 49.4, compared with a 10-year median of 58.6.
What is Boston Scientific's EV/EBITDA?
Boston Scientific's enterprise value was 30.0 times EBITDA at the end of fiscal 2025 (enterprise value $152.9 billion, EBITDA $5.1 billion); the current EV/EBITDA is 13.6.
What is Boston Scientific's return on equity?
Boston Scientific's return on equity (ROE) was 12.5% in fiscal 2025: net income of $2.9 billion on average shareholders' equity of $23.0 billion.
What is Boston Scientific's ROIC?
Boston Scientific's return on invested capital was 10.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Boston Scientific have?
Boston Scientific had total debt of $12.4 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.51 and $10.4 billion of net debt (2.03 times EBITDA).
What is Boston Scientific's free cash flow yield?
Boston Scientific generated $3.7 billion of free cash flow in fiscal 2025, a free cash flow yield of 2.6% on its market value at year-end ($142.5 billion).
What is Boston Scientific's current ratio?
Boston Scientific's current ratio was 1.62 at the end of fiscal 2025: current assets were 1.62 times current liabilities.